USANA Ranked #1 Direct Selling Brand for Calcium Supplements in Hong Kong
Euromonitor International honors USANA Hong Kong HONG KONG, March 30, 2023 /PRNewswire/ -- USANA Hong Kong was recently recognized as a top brand for calcium supplements by market research giant Euromonitor International. This distinction is based on market research of USANA's MagneCal D supplement and its retail value sales data compared to...
ImmVira’s oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA’s approval for Clinical Trial in China
SHENZHEN, China, March 30, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial in China on March 29, 2023. Previously, MVR-C5252 also obtained Orphan Drug Designation from U.S. Food and Drug Administration in August 2022. ...
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as of March 29, 2023, the company has conducted 13 clinical studies covering hematologic malignancies, solid tumors and autoimmune diseases, and its cell immunotherapy drugs (marketed products and candidate drugs included) have...
Zimmer Biomet’s ROSA HIP with ONE Planner Hip Awarded Orthopaedic Product Innovation of the Year by Healthcare Asia Medtech Awards 2023
SINGAPORE , March 30, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that ROSA HIP® with ONE Planner™ Hip won the "Orthopaedic Product Innovation of the Year" at this year's Healthcare Asia Medtech Awards. As a precisely personalized robotic system, ROSA HIP® enables...
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
- ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease - LOS ANGELES, March 30, 2023 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule...
Broncus Medical (02216.HK) Announces Annual Results for 2022
Product sales in China for 2022 increased 50% compared to the same period in 2021, while product development and commercialization are steadily advancing. HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Broncus Medical (02216.HK), a leader in precise interventional diagnosis and therapy of lung diseases in China, announced its annual results for the year ended December 31,...
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy
GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, Health Minister Ong Ye Kung, Senior Minister of State for Foreign Affairs and National Development...
LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results. During the year ended 31 December 2022, Lifetech achieved a revenue of approximately RMB1,097.3 million, increased by 18.6%...
bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases
-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku, Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-ku, Tokyo; President: Hiroyuki Horiuchi; hereafter 'Kaken') have signed a joint research agreement on the discovery of drugs for infectious...
CHINA LIFE INSURANCE COMPANY LIMITED ANNOUNCES 2022 ANNUAL RESULTS (H SHARES)
HONG KONG, March 29, 2023 /PRNewswire/ -- China Life Insurance Company Limited (SSE: 601628, SEHK: 2628) announces the audited consolidated results of the Company (China Life Insurance Company Limited and its subsidiaries) for the year ended 31 December 2022 (the "Reporting Period") prepared under the International Financial Reporting Standards today. Financial Summary As at the...
